AV-MEL-1

AV-MEL-1 is an autologous dendritic cell vaccine developed as a personalized immunotherapy for metastatic melanoma. The therapy consists of autologous dendritic cells loaded with antigens derived from the patient's own tumor-initiating cells, aiming to stimulate the immune system to recognize and attack melanoma cells. It is administered by injection, often in combination with anti-PD-1 checkpoint inhibitors such as pembrolizumab or nivolumab. The vaccine is designed to enhance immune response against melanoma and has shown promising safety and efficacy signals in early clinical studies, including reports of durable complete remission in some patients when combined with anti-PD-1 therapy[1][3][7].

Other names

AV MEL 1